Nusaibah Ibrahimi
Villejuif, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Author Correction: High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer.
Journal: Nature communications
Published: November 14, 2022
Dynamics of circulating calprotectin accurately predict the outcome of moderate COVID-19 patients.
Journal: EBioMedicine
Published: February 18, 2022
Covid-19 vaccines available in Europe. New data
Journal: La Revue du praticien
Published: February 11, 2022
Outcomes of Patients With Active Cancer and COVID-19 in the Intensive-Care Unit: A Multicenter Ambispective Study.
Journal: Frontiers in oncology
Published: January 19, 2022
Delivering adapted physical activity by videoconference to patients with fatigue under immune checkpoint inhibitors: Lessons learned from the PACTIMe-FEAS feasibility study.
Journal: Journal of telemedicine and telecare
Published: June 17, 2021
Severe COVID-19 in patients with hematological cancers presenting with viremia.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: April 05, 2021
High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer.
Journal: Nature communications
Published: February 22, 2021
Showing 1-9 of 9
Last Updated: 09/26/2026